The novel of COVID-19 disease started in late 2019 making the worldwide governments came across a high number of critical and death cases,beyond constant fear of the collapse in their health *** the beginning of the p...
详细信息
The novel of COVID-19 disease started in late 2019 making the worldwide governments came across a high number of critical and death cases,beyond constant fear of the collapse in their health *** the beginning of the pandemic,researchers and authorities are mainly concerned with carrying out quantitative studies(modeling and predictions)overcoming the scarcity of tests that lead us to under-reporting *** address these issues,we introduce a Bayesian approach to the SIR model with correction for underreporting in the analysis of COVID-19 cases in *** proposed model was enforced to obtain estimates of important quantities such as the reproductive rate and the average infection period,along with the more likely date when the pandemic peak may *** under-reporting scenarios were considered in the simulation study,showing how impacting is the lack of information in the modeling.
OBJECTIVES Elderly patients show a higher incidence of ischemic and bleeding events after percutaneous transluminal coron-ary intervention(PCI).We sought to investigate outcomes in elderly patients treated with antith...
详细信息
OBJECTIVES Elderly patients show a higher incidence of ischemic and bleeding events after percutaneous transluminal coron-ary intervention(PCI).We sought to investigate outcomes in elderly patients treated with antithrombotic strategy guided by bleeding and ischemic risks after revascularization with last generation everolimus-eluting stent(EES).METHODS Prospective multicenter registry including patients over 75 years revascularized with EES and antithrombotic ther-apy guided by clinical presentation,PCI complexity and PRECISE DAPT ***-primary safety endpoints were:(1)composite of cardiac death,myocardial infarction and stent thrombosis and;(2)bleeding(BARC 2-5).Primary efficacy endpoint was target lesion revascularization.A matched group of patients revascularized with current drug-eluting stents and no such tailored antith-rombotic therapy was used as *** Finally,1064 patients were included in SIERRA-75 cohort,80.8±4.2 years,36.6%women,71%acute coronary syn-dromes(ACS)and 53.6%complex ***-primary safety endpoint of major adverse cardiovascular events was met in 6.2%,co-primary safety endpoint of bleeding in 7.8%and primary efficacy endpoint of TKLR in 1.5%.The multivariable adjusted model showed no significant association of the prescribed short/long dual antiplatelet therapy(DAPT)durations with any endpoint suggesting a well tailored *** stent thrombosis reported in the subgroup with 1-3 months DAPT *** compared to control group,bleeding BARC 2-5 was significantly lower in SIERRA-75 group(7.4%vs.10.2%,P=0.04)as well as the net safety-efficacy endpoint(14.3%vs.18.5%,P=0.02).CONCLUSIONS In elderly population,the application of this risks-adjusted antithrombotic protocol after revascularization with last generation EES seems to be associated with an improved prognosis in terms of ischemic and bleeding outcomes.
暂无评论